Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
Meeting ReportMolecular Targeting Probes - Radioactive & Nonradioactive

Human dosimetry of 89Zr-trastuzumab-PET in patients with HER2-positive breast cancer

Richard Laforest, Suzanne Lapi, Ron Bose, Adel Tabchy, Reiko Oyama, Bernadette Marquez, Jennifer Burkemper, Brian Wright, Barry Siegel and Farrokh Dehdashti
Journal of Nuclear Medicine May 2015, 56 (supplement 3) 1024;
Richard Laforest
1Radiology, Washington University Medical School, St.Louis, MO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Suzanne Lapi
1Radiology, Washington University Medical School, St.Louis, MO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ron Bose
2Int.Med. Medical Oncology, Washington University, St.Louis, MO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adel Tabchy
2Int.Med. Medical Oncology, Washington University, St.Louis, MO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Reiko Oyama
1Radiology, Washington University Medical School, St.Louis, MO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bernadette Marquez
1Radiology, Washington University Medical School, St.Louis, MO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer Burkemper
1Radiology, Washington University Medical School, St.Louis, MO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brian Wright
1Radiology, Washington University Medical School, St.Louis, MO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Barry Siegel
1Radiology, Washington University Medical School, St.Louis, MO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Farrokh Dehdashti
1Radiology, Washington University Medical School, St.Louis, MO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

1024

Objectives Human epidermal growth factor receptor 2 (HER2) is expressed in approximately 25% of all breast cancers; its overexpression is associated with more aggressive disease. In vivo measurement of HER2 expression offers several advantages, including the ability to assess HER2 expression in all parts of the tumor and in multiple lesions, many of which may be inaccessible to biopsy; to assess in vivo availability of HER2; and to monitor therapeutic effects on HER2 expression. The objective of this study was to estimate radiation dosimetry with 89Zr-trastuzumab and to determine the optimal imaging time in patients with HER2-positive breast cancer.

Methods 89Zr-trastuzumab was prepared as in[1,2]. Eleven women with biopsy-proven HER2-positive breast cancer were injected with ~2 mCi of 89Zr-trastuzumab and underwent PET/CT twice between 0 and 6 days after administration. Trastuzumab-naïve patients received 50 mg trastuzumab and patients under trastuzumab therapy received 10 mg, typically 30 min to 2 hours before 89Zr-trastuzumab injection. Images were reconstructed with 3D OSEM, 3it/21subsetsand Gaussian smoothing of 7 mm. Pharmacokinetic data were obtained from whole-torso PET images and organ time-activity curves were created by collating data from all patients. Human dosimetry estimates were obtained from the residence times and OLINDA with the adult female model.

Results High-quality images and best tumor-to-nontumor contrast were achieved on the images acquired at 5 ± 1 day after injection. The tracer was predominantly retained in the liver (~15% ID versus ~5% ID based on animal data), remaining constant over time, and the liver thus was the critical organ with a dose of 1.54 mSv/MBq (5.68 rad/mCi). Theeffective dose was 0.47 mSv/MBq (1.74 rem/mCi).

Conclusions The best imaging time is at least 4 days after administration of 89Zr-trastuzumab. The radiation dose to the liver was greater than calculated using animal dosimetry data.

Research Support This work was supported by the NIH by 1R21CA182945-01

Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 56, Issue supplement 3
May 1, 2015
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Human dosimetry of 89Zr-trastuzumab-PET in patients with HER2-positive breast cancer
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Human dosimetry of 89Zr-trastuzumab-PET in patients with HER2-positive breast cancer
Richard Laforest, Suzanne Lapi, Ron Bose, Adel Tabchy, Reiko Oyama, Bernadette Marquez, Jennifer Burkemper, Brian Wright, Barry Siegel, Farrokh Dehdashti
Journal of Nuclear Medicine May 2015, 56 (supplement 3) 1024;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Human dosimetry of 89Zr-trastuzumab-PET in patients with HER2-positive breast cancer
Richard Laforest, Suzanne Lapi, Ron Bose, Adel Tabchy, Reiko Oyama, Bernadette Marquez, Jennifer Burkemper, Brian Wright, Barry Siegel, Farrokh Dehdashti
Journal of Nuclear Medicine May 2015, 56 (supplement 3) 1024;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Molecular Targeting Probes - Radioactive & Nonradioactive

  • Synthesis and Preliminary Evaluation of Metabolically Stable 18F-Lableled PET Tracer for Fatty Acid Beta-Oxidation Imaging.
  • 18F-Radiofluorination of Aryl C-H Bonds using a Tandem Ir C-H Borylation/Cu Radiofluorination Strategy
  • Predictive modeling of tau aggregation and propagation using PET and DTI
Show more Molecular Targeting Probes - Radioactive & Nonradioactive

Special MTA: Dosimetry Posters

  • Radiation dosimetry estimates of 64CuCl2 based on biodistribution data of rats
  • Impact of FDG Dose Reduction on Lesion Quantification in Dynamic PET - A Simulation Study Based on Clinical Trial Data
  • Therapeutic effect on collagen induced arthritis assessed by 18F-FDG PET and DCE-MRI in rats
Show more Special MTA: Dosimetry Posters

Similar Articles

SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire